1. Home
  2. HBB vs SGHT Comparison

HBB vs SGHT Comparison

Compare HBB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hamilton Beach Brands Holding Company

HBB

Hamilton Beach Brands Holding Company

N/A

Current Price

$16.23

Market Cap

236.4M

ML Signal

N/A

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$3.88

Market Cap

282.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBB
SGHT
Founded
1904
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.4M
282.9M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
HBB
SGHT
Price
$16.23
$3.88
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
20.7K
359.7K
Earning Date
06-01-2026
06-01-2026
Dividend Yield
2.93%
N/A
EPS Growth
N/A
28.16
EPS
1.95
N/A
Revenue
$606,852,000.00
$77,363,000.00
Revenue This Year
N/A
$13.54
Revenue Next Year
N/A
$14.53
P/E Ratio
$8.39
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.72
$2.03
52 Week High
$20.75
$9.24

Technical Indicators

Market Signals
Indicator
HBB
SGHT
Relative Strength Index (RSI) 44.06 34.27
Support Level $15.77 $3.26
Resistance Level $17.14 $4.33
Average True Range (ATR) 1.06 0.34
MACD -0.19 -0.05
Stochastic Oscillator 23.20 14.76

Price Performance

Historical Comparison
HBB
SGHT

About HBB Hamilton Beach Brands Holding Company

Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: